Time-to-progression after frontline chemoimmunotherapy for chronic lymphocytic leukemia: an independently validated retrospective cohort study

BACKGROUND: Because frontline treatment with FCR unequivocally improves progression-free and overall survival in CLL patients, it has become a “gold standard” for chemoimmunotherapy regimens. Follow-up studies show that a subset of generally young, physically-fit patients with mutated IGHV genes and...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Lancet Oncol
Prif Awduron: Herling, Carmen D., Coombes, Kevin R., Benner, Axel, Bloehdorn, Johannes, Barron, Lynn L., Abrams, Zachary B., Majewski, Tadeusz, Bondaruk, Jolanta E., Bahlo, Jasmin, Fischer, Kirsten, Hallek, Michael, Stilgenbauer, Stephan, Czerniak, Bogdan A., Oakes, Christopher, Ferrajoli, Alessandra, Keating, Michael J., Abruzzo, Lynne V.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7147008/
https://ncbi.nlm.nih.gov/pubmed/31582354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(19)30503-0
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg